Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study.
Lacroix A, Bronstein MD, Schopohl J, Delibasi T, Salvatori R, Li Y, Barkan A, Suzaki N, Tauchmanova L, Ortmann CE, Ravichandran S, Petersenn S, Pivonello R.
Lacroix A, et al. Among authors: ravichandran s.
J Endocrinol Invest. 2020 Nov;43(11):1613-1622. doi: 10.1007/s40618-020-01246-0. Epub 2020 May 8.
J Endocrinol Invest. 2020.
PMID: 32385851
Clinical Trial.